Key Highlights

  • Healius shares rose 4.22% to $0.433 during the trading session on 23 October 2026, while the S&P/ASX 200 was down 0.35%.
  • The company agreed on 25 September 2026 to dispose of Agilex Biolabs to a Novotech subsidiary for an enterprise value of A$160 million.
  • Completion is anticipated during H2 FY 2027, subject to FIRB and ACCC approvals, with Healius expecting to move to a net cash position.

Shares in Healius Limited (ASX:HLS) rose 4.22% to $0.433 during the trading session on 23 October 2026, as at 12:04 pm, while the S&P/ASX 200 stood at 8,762.60, down 0.35% (30.60 points) at the same time. Healius is an Australian healthcare company that provides specialty pathology services across the country through its network of centres. In an ASX announcement dated 25 September 2026, the company reported that it had entered into a binding agreement for the sale of its wholly owned subsidiary, Agilex Biolabs, to a subsidiary of Novotech Health Holdings.

Binding Agreement for the Sale of Agilex Biolabs

In its announcement dated 25 September 2026, Healius said it had signed a binding agreement for the sale of Agilex Biolabs Pty Ltd, a wholly owned subsidiary, to a subsidiary of Novotech Health Holdings Pte Ltd. The transaction values the business at an enterprise value of A$160 million.

On a pre-AASB16 basis, the company stated that the price represents a multiple of 19.8x Agilex Biolabs' FY2026 EBITDA. That figure is calculated from FY26 EBITDA of $10.7 million less an AASB 16 property lease impact of $2.6 million.

Expected Proceeds, Tax and Balance Sheet Position

Healius reported on 25 September 2026 that the transaction is expected to deliver cash proceeds of approximately $155 million after all separation and transaction costs, subject to typical completion adjustments relating to working capital, cash and debt. The company does not expect to incur any tax in relation to the transaction.

The announcement stated that, once the sale is completed, Healius will be in a net cash position. The company said it will provide further details on its intentions for the sale proceeds closer to completion.

Background to the Sale Process and Conditions

According to the announcement dated 25 September 2026, Healius commenced a process in May 2026 to explore a sale of Agilex Biolabs in response to several unsolicited approaches from credible parties. The company said it determined that a disposal at a sufficiently attractive price would support management focus on the ongoing growth of its core Pathology business.

Agilex Biolabs operates as a standalone business under Healius, and the company said the sale will not affect its Pathology operations. UBS Securities Australia Limited is acting as financial adviser and Mallesons as legal adviser to Healius.

About the Company and Business Overview

Healius Limited (ASX: HLS) is listed on the Australian Securities Exchange and has its registered office at Level 22, 161 Castlereagh Street, Sydney, New South Wales. For over 30 years the company has described itself as one of Australia's leading healthcare companies. Through its footprint of centres and more than 8,000 employees, Healius provides Australia-wide specialty pathology services to consumers and their referring practitioners.

Its core Pathology business delivers diagnostic services to millions of Australians each year, according to the company. Agilex Biolabs, the subsidiary being sold, operates as a standalone business within the group. The buyer's parent, Novotech, is a clinical research organisation that runs trials across all phases and sizes and is majority controlled by private investment funds affiliated with TPG.

Related Sector Context

Healius operates in the healthcare services sector, where pathology providers supply diagnostic testing that supports clinical decisions made by referring practitioners. Clinical research organisations, the area in which Novotech operates, serve biotechnology and pharmaceutical customers.

On the broader market, the S&P/ASX 200 stood at 8,762.60 at 12:04 pm on 23 October 2026, down 0.35%. Healius shares were trading higher at the same point in the session.

Risks to Weigh In

The sale of Agilex Biolabs has not yet been completed. The company stated that completion remains subject to conditions, including approvals from the Foreign Investment Review Board and the Australian Competition and Consumer Commission, and the outcome of those regulatory processes is not within the company's control.

Proceeds of approximately $155 million are also subject to typical completion adjustments relating to working capital, cash and debt. The announcement also notes that forward-looking statements are subject to risks and uncertainties, many beyond Healius' control. Following completion, the group would rely on its Pathology business alone, which the company describes as its core operation.

Catalysts on Watch

The key milestone stated in the announcement is completion of the transaction, which Healius expects during H2 FY 2027, subject to the satisfaction of all conditions. Decisions from the two regulators are the named conditions.

The company has also said it will provide further details on its intentions for the sale proceeds closer to completion, along with its assessment of capital requirements.

Where Things Stand

Healius shares were up 4.22% at $0.433 during the session on 23 October 2026, with the S&P/ASX 200 down 0.35% at 8,762.60. The most recent company update on file is the 25 September 2026 announcement of the binding agreement to dispose of Agilex Biolabs for A$160 million, with completion anticipated during H2 FY 2027 and approvals pending.